s6y

IGC Pharma, Inc.

Ticker
IGC
CIK
1326205
Industry
Pharmaceutical Preparations
Formerly
India Globalization Capital, Inc.

Financials 114

  1. 10-Q Quarterly Report for period ending Sep 30, 2026
  2. 10-Q Quarterly Report for period ending Jun 30, 2026
  3. 10-Q Quarterly Report for period ending Mar 31, 2026
  4. 10-KT Transition report pursuant to Rule 13a-10 or 15d-10 for period ending Dec 31, 2025
  5. 10-Q Quarterly Report for period ending Sep 30, 2025
  6. 10-Q Quarterly Report for period ending Jun 30, 2025
  7. 10-K Annual Report for period ending Mar 31, 2025
  8. 10-Q Quarterly Report for period ending Dec 31, 2024
  9. 10-Q Quarterly Report for period ending Sep 30, 2024
  10. 10-Q Quarterly Report for period ending Jun 30, 2024

All 114 financials filings

News 191

  1. 8-K Current report filing
  2. 8-K Current report filing
  3. 8-K Current report filing
  4. 8-K Current report filing
  5. 8-K Current report filing
  6. 8-K Current report filing
  7. 8-K Current report filing
  8. 8-K Current report filing
  9. 8-K Current report filing
  10. 8-K Current report filing

All 191 news filings

Ownership 222

  1. 4 Statement of changes in beneficial ownership of securities
  2. 4 Statement of changes in beneficial ownership of securities
  3. 4 Statement of changes in beneficial ownership of securities
  4. 4 Statement of changes in beneficial ownership of securities
  5. 4 Statement of changes in beneficial ownership of securities
  6. 4 Statement of changes in beneficial ownership of securities
  7. 4 Statement of changes in beneficial ownership of securities
  8. 4 Statement of changes in beneficial ownership of securities
  9. 4 Statement of changes in beneficial ownership of securities
  10. 4 Statement of changes in beneficial ownership of securities

All 222 ownership filings

Prospectus 84

  1. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  2. S-3/A Registration statement for specified transactions by certain issuers
  3. S-3 Registration statement for specified transactions by certain issuers
  4. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  5. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  6. S-3 Registration statement for specified transactions by certain issuers
  7. S-3 Registration statement for specified transactions by certain issuers
  8. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  9. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  10. S-3 Registration statement for specified transactions by certain issuers

All 84 prospectus filings

Proxies 38

  1. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  2. DEF 14A Definitive proxy statements
  3. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  4. DEF 14A Definitive proxy statements
  5. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  6. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  7. DEF 14A Definitive proxy statements
  8. DEF 14A Definitive proxy statements
  9. DEF 14A Definitive proxy statements
  10. DEF 14A Definitive proxy statements

All 38 proxies filings

Other 169

  1. EFFECT Notice of Effectiveness
  2. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  3. EFFECT Notice of Effectiveness
  4. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  5. UPLOAD Letter (PDF)
  6. 144 Filing for proposed sale of securities under Rule 144
  7. UPLOAD Letter (PDF)
  8. EFFECT Notice of Effectiveness
  9. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  10. UPLOAD Letter (PDF)

All 169 other filings